The latest price target for Genmab (NASDAQ:GMAB) was reported by HC Wainwright & Co. on January 28, 2026. The analyst firm set a price target for $39.00 expecting GMAB to rise to within 12 months (a possible 26.21% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Genmab (NASDAQ:GMAB) was provided by HC Wainwright & Co., and Genmab reiterated their buy rating.

The last upgrade for Genmab AS happened on September 24, 2025 when Guggenheim raised their price target to $43. Guggenheim previously had a neutral for Genmab AS.

The last downgrade for Genmab AS happened on August 20, 2024 when JP Morgan changed their price target from N/A to N/A for Genmab AS.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Genmab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Genmab was filed on January 28, 2026 so you should expect the next rating to be made available sometime around January 28, 2027.

While ratings are subjective and will change, the latest Genmab (GMAB) rating was a reiterated with a price target of $39.00 to $39.00. The current price Genmab (GMAB) is trading at is $30.90, which is out of the analyst’s predicted range.